{
    "clinical_study": {
        "@rank": "36772", 
        "arm_group": {
            "arm_group_label": "Infliximab", 
            "description": "Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial."
        }, 
        "biospec_descr": {
            "textblock": "Serum samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The aim of the study was to evaluate the efficacy of infliximab (IFX) treatment, 5 mg/kg\n      every 6 weeks, in patients with active ankylosing spondylitis (AS) and to determine whether\n      IFX dose reduction and interval extension, 3 mg/kg every 8 weeks  during the second year\n      sustained the treatment effect. The study was started in 2003 an finished in 2008."
        }, 
        "brief_title": "Remicade in the Treatment of Patients With Active Ankylosing Spondylitis", 
        "completion_date": {
            "#text": "May 2008", 
            "@type": "Actual"
        }, 
        "condition": "Ankylosing Spondylitis", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The patients had to fulfill the following four inclusion criteria:\n\n        (I) Age between 18 and 60 years, (II) proven diagnosis according to the modified New York\n        criteria 12 for definitive AS, (III) active disease with Bath AS Disease Activity Index\n        (BASDAI) score above 4 and (IV) current or previous treatment with conventional\n        non-steroidal anti-inflammatory drugs (NSAID) in adequate doses without sufficient effect.\n\n        Exclusion Criteria:\n\n          -  current signs or symptoms of severe, progressive or uncontrolled hepatic,\n             hematological, pulmonary, cardiac, neurological or cerebral disease;\n\n          -  ongoing or past serious infection (including HIV and past or current tuberculosis);\n\n          -  pregnancy or breast feeding;\n\n          -  current malignancy or history of malignancy within the past five years;\n\n          -  congestive heart failure and any contraindication to MRI."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with active ankylosing spondylitis with BASDAI>4"
            }
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850121", 
            "org_study_id": "2002-11-04 amended 2002-01-08"
        }, 
        "intervention": {
            "arm_group_label": "Infliximab", 
            "description": "5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.", 
            "intervention_name": "Infliximab", 
            "intervention_type": "Drug", 
            "other_name": "Remicade"
        }, 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ankylosing Spondylitis", 
            "infiximab", 
            "single armed trial"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gothenburg", 
                    "country": "Sweden", 
                    "zip": "S-413 45"
                }, 
                "name": "Sahlgrenska University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "Remicade in the Treatment of Patients With Active Ankylosing Spondylitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion of responders at week 16 defined as a reduction of 50% and/or 2 units improvement from baseline of Bath AS disease activity score (BASDAI)", 
            "measure": "Bath AS disease activity score (BASDAI)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850121"
        }, 
        "responsible_party": {
            "investigator_affiliation": "G\u00f6teborg University", 
            "investigator_full_name": "Helena Forsblad d'Elia", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "G\u00f6teborg University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "G\u00f6teborg University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}